Medicine

Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma?

Timothy Illidge
Timothy Illidge

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
TIMOTHY ILLIDGE, Christie Hospital, Manchester
Radioconjugated antibodies are showing great promise for treating follicular lymphoma which has failed chemotherapy combined with rituximab. That’s according to Tim Illidge who told the Paris conference that tositumomab and ibritumomab tiuxetan have already proved effective. He explained to Peter Goodwin why he thinks the latest data look promising.

Download this interview

Similar Interviews

  • Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma
  • Sandra Horning Abstract 349 Sandra Horning, Stanford University Medical Center It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine,

  • Live Report from ASH:
    Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
  • Anton Hagenbeek ANTON HAGENBEEK, University Medical Centre Utrecht For patients with advanced-stage follicular non-Hodgkin’s

  • Audio Journal of Oncology 14.2, March 2006
  • Reporting from: American Society of Hematology Meeting, Atlanta, 10-13 December 2005 Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of

    Post a comment